If the FDA approves MDMA (also known as ecstasy) as a treatment for PTSD (post-traumatic stress disorder) by mid-2027, it won't be a clean, straightforward approval. The agency will attach strict controls — things like a special safety program limiting which doctors can prescribe it, requirements on who can distribute it, or mandatory follow-up studies to collect more data. This matters because those restrictions would limit how many patients could actually access the treatment, even after approval.
Functional unblinding and durability gaps from prior reviews persist. Reform is conditional; the agency will attach risk-mitigation requirements rather than grant unconditional approval.